Hence, we challenged tumor organoids with sorafenib, the FDA-approved drug for treating advanced HCC, and compared the relative potential of LGR5–GFP+ and LGR5–GFP− cells to withstand such treatment (Fig. 5a). This evidence concerns the gene LGR5 and neoplasm.